SAN DIEGO, June 28 /PRNewswire/ -- Nereus Pharmaceuticals, Inc., a pioneer in drug discovery and development from marine microbial sources, today announced Charles White, Ph.D., was appointed Chief Business Officer. Dr. White is responsible for overall business leadership with a focus on negotiating partnerships and licensing agreements with pharmaceutical, biotech and academic collaborators.
“Dr. White’s extensive experience in all aspects of business development within the pharmaceutical industry makes him an excellent addition to the Nereus team. He will lead our initiative to establish partnerships to advance our clinical development programs and alliances to capitalize on our drug discovery efforts,” said Kobi M. Sethna, President and CEO of Nereus Pharmaceuticals, Inc.
Dr. White has over 25 years business development and marketing experience in the industry, working most recently as Vice President of Biotechnology Business Development at Organon, the pharmaceutical business unit of Akzo Nobel. Prior to Organon, Dr. White was Vice President at Diosynth, which recently merged with Organon, and was responsible for business development and M&A activities. He also held Vice President positions with Diosynth’s predecessors, Corning Bio and Covance Biotechnology Services, where he was head of business development. Dr. White has also held various business development and marketing positions with Medisorb Technologies and E.I. DuPont Company. He received a Ph.D. in chemistry from the University of California, Berkeley and a B.S. in chemistry from the Georgia Institute of Technology.
About Nereus Pharmaceuticals, Inc.
Nereus Pharmaceuticals pursues untapped sources of chemical diversity to discover and develop novel therapeutics. With unmatched expertise in marine microbiology and integrated technologies to identify and synthesize novel biologically active compounds, the Company’s two oncology drug candidates are in Phase I clinical trials. NPI-2358, a tumor vascular disrupting agent, is being evaluated for solid tumors, and proteasome inhibitor NPI-0052 is being developed for solid tumors, lymphomas and multiple myeloma. Nereus’ discovery portfolio also includes additional drug candidates for oncology, as well as infectious diseases and inflammation. The Company is privately held and based in San Diego, California. For more information, visit www.nereuspharm.com.
Nereus Pharmaceuticals is a registered trademark of Nereus Pharmaceuticals, Inc.
Nereus Pharmaceuticals, Inc.
CONTACT: Kobi M. Sethna, President & CEO of Nereus Pharmaceuticals, Inc.,+1-858-587-4093; or Media & Investor Relations, Pam Lord of Porter NovelliLife Sciences, +1-858-527-3494, plord@pnlifesciences.com, for NereusPharmaceuticals, Inc.
Web site: http://www.nereuspharm.com/
